X4 Pharmaceuticals (XFOR) Misses Q4 EPS by 4c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q4 EPS of ($0.20), $0.04 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.43 million versus the consensus estimate of $990.71 thousand.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Deere conference call: 2027 orders up mid-single digits from last year)
• UBS Reiterates Buy Rating on Dutch Bros Inc. (BROS): 'One of Strongest Growth Stories in Restaurants'
• Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings